vers la météo de la validation par utilisateur
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+ +----------------------------------APPOS----------------------------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (administration,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | | +--------------------------APPOS--------------------------+ | | +MOD_ATT:N-AD+ | +-------APPOS------+ | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (bezafibrate,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +------------COMP:N-N(of)------------+ +----------------------------------APPOS----------------------------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (administration,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+------------COMP:N-N(of)------------+ | +----------------------------------APPOS----------------------------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (administration,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +--------------------------APPOS--------------------------+ | | +MOD_ATT:N-AD+ | +---MOD_ATT:N-ADJ--+ | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (bezafibrate,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +--------------------------APPOS--------------------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+ | | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (bezafibrate,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +----------------------------------APPOS----------------------------------+ | | +MOD_ATT:N-AD+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (administration,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+------------COMP:N-N(of)------------+ | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | +-----COMP:N-N(from)----+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +MOD_ATT:N-AD+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | +-----COMP:N-N(from)----+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +MOD_ATT:N-AD+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ | +------------------COMP:N-N(with)-----------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ | +-----COMP:N-N(from)----+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ +---COMP:N-N(of)---+ | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+ | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+ | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ +-------APPOS------+ +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ | | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | +-------APPOS------+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+ | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +-------------------COMP:N-N(of)------------------+ | | +------------COMP:N-N(of)------------+ | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | +-------APPOS------+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +----------------------------COMP:N-N(of)----------------------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(of) (liver,__NODE__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+ | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ +---COMP:N-N(of)---+ | +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +MOD_ATT:N-AD+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +----------------------------COMP:N-N(of)----------------------------+ | +------------------COMP:N-N(with)-----------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) COMP:N-N(of) (liver,__NODE__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ | +-------APPOS------+ +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ +-------APPOS------+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ +-------APPOS------+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ | +-------APPOS------+ +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ +-------APPOS------+ +-COMP:N-N(of)-+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------------COMP:N-N(of)------------------+ | | | | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------------COMP:N-N(of)------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ +-------APPOS------+ +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ | +-----COMP:N-N(from)----+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------------COMP:N-N(of)------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ +-------APPOS------+ +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ +---COMP:N-N(of)---+ | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------------COMP:N-N(of)------------------+ | | | | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ +---COMP:N-N(of)---+ | +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +----------------------------COMP:N-N(of)----------------------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ | | | +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) COMP:N-N(of) (liver,__NODE__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------------COMP:N-N(of)------------------+ | | | | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ +---COMP:N-N(of)---+ | +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +MOD_ATT:N-AD+ +---COMP:N-N(of)---+ | +-COMP:N-N(of)-+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | +----------------COMP:N-N(of)----------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------------COMP:N-N(of)------------------+ | | +------------COMP:N-N(of)------------+ | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | +MOD_ATT:N-AD+ | +-------APPOS------+ +-COMP:N-N(of)-+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +-------------------COMP:N-N(of)------------------+ | | +----------------COMP:N-N(of)----------------+ | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ | | +-------APPOS------+ +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | | +-------------------COMP:N-N(of)------------------+ | | | | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ | +-------APPOS------+ +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+------------COMP:N-N(of)------------+ | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+ | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ +---COMP:N-N(of)---+ | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ +---COMP:N-N(of)---+ | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ +-------APPOS------+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +------------COMP:N-N(of)------------+ | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +----------------------------COMP:N-N(of)----------------------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(of) (liver,__NODE__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ +-------APPOS------+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +----------------------------COMP:N-N(of)----------------------------+ | +------------------COMP:N-N(with)-----------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) COMP:N-N(of) (liver,__NODE__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +----------------COMP:N-N(of)----------------+ | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ +---COMP:N-N(of)---+ | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ | +------------------COMP:N-N(with)-----------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | +-------APPOS------+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | +------------COMP:N-N(of)------------+ | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | +--------------------------APPOS--------------------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ +---MOD_ATT:N-ADJ--+ | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (bezafibrate,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | +--------------------------APPOS--------------------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ +---MOD_ATT:N-ADJ--+ | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (bezafibrate,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+ | +--------------------------APPOS--------------------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (bezafibrate,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +--------------------------APPOS--------------------------+ | | +MOD_ATT:N-AD+ +---COMP:N-N(of)---+ | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (bezafibrate,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | +----------------------------------APPOS----------------------------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ +-------APPOS------+ +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (administration,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +------------COMP:N-N(of)------------+ +----------------------------------APPOS----------------------------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (administration,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +----------------------------COMP:N-N(of)----------------------------+ | +------------------COMP:N-N(with)-----------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +--------------------------APPOS--------------------------+ | | +MOD_ATT:N-AD+ | | | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) COMP:N-N(of) (liver,__NODE__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (bezafibrate,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | | +----------------------------------APPOS----------------------------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (administration,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +-----COMP:N-N(from)----+ +-------------------------------------------SUBJ:V-N------------------------------------------+ | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+------------COMP:N-N(of)------------+ | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | +-----COMP:N-N(from)----+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +MOD_ATT:N-AD+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ | +------------------COMP:N-N(with)-----------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+ | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+ | +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ +---COMP:N-N(of)---+ | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +-------------------COMP:N-N(of)------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +------------COMP:N-N(of)------------+ | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ +-----COMP:N-N(from)----+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +MOD_ATT:N-AD+ +---COMP:N-N(of)---+ | +-COMP:N-N(of)-+ | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ +---COMP:N-N(of)---+ | +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+ | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+ | +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | +-------APPOS------+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ +-------APPOS------+ +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | +-------APPOS------+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +-----COMP:N-N(from)----+------------COMP:N-N(of)------------+ +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+ | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | +------------COMP:N-N(of)------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+ | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+------------COMP:N-N(of)------------+ | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ | | +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +----------------------------COMP:N-N(of)----------------------------+ | +------------------COMP:N-N(with)-----------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) COMP:N-N(of) (liver,__NODE__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +----------------------------COMP:N-N(of)----------------------------+ | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(of) (liver,__NODE__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ | +-------APPOS------+ +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +MOD_ATT:N-AD+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +-------------------COMP:N-N(of)------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+ | +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | +------------COMP:N-N(of)------------+ | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------------COMP:N-N(of)------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ +-------APPOS------+ +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ | +-----COMP:N-N(from)----+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+ | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ +---COMP:N-N(of)---+ | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +----------------COMP:N-N(of)----------------+ | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ | | +-------APPOS------+ +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------------COMP:N-N(of)------------------+ | | | | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ +---COMP:N-N(of)---+ | +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +MOD_ATT:N-AD+ | | +-COMP:N-N(of)-+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------------COMP:N-N(of)------------------+ | | | | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ | | +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+------------COMP:N-N(of)------------+ | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+---COMP:N-N(of)---+ | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ +---COMP:N-N(of)---+ | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ +---COMP:N-N(of)---+ | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ +-------APPOS------+ +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +------------COMP:N-N(of)------------+ | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ +---COMP:N-N(of)---+ | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +------------COMP:N-N(of)------------+ | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | +-------APPOS------+ +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +----------------------------COMP:N-N(of)----------------------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(of) (liver,__NODE__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +----------------------------COMP:N-N(of)----------------------------+ | +------------------COMP:N-N(with)-----------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) COMP:N-N(of) (liver,__NODE__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +----------------COMP:N-N(of)----------------+ | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ +---COMP:N-N(of)---+ | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ +----------------------------------APPOS----------------------------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (administration,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+------------COMP:N-N(of)------------+ | +--------------------------APPOS--------------------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (bezafibrate,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+------------COMP:N-N(of)------------+ | +--------------------------APPOS--------------------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (bezafibrate,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+------------COMP:N-N(of)------------+ +----------------------------------APPOS----------------------------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (administration,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +--------------------------APPOS--------------------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (bezafibrate,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +--------------------------APPOS--------------------------+ | | +MOD_ATT:N-AD+ | | +---MOD_ATT:N-ADJ--+ | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (bezafibrate,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +--------------------------APPOS--------------------------+ | | +MOD_ATT:N-AD+ | | +---MOD_ATT:N-ADJ--+ | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (bezafibrate,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | +--------------------------APPOS--------------------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ +-------APPOS------+ | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (bezafibrate,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | +----------------------------------APPOS----------------------------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (administration,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +--------------------------APPOS--------------------------+ | | +-MOD_ATT:N-N+ +---COMP:N-N(of)---+ | | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (bezafibrate,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +------------COMP:N-N(of)------------+ | +--------------------------APPOS--------------------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (bezafibrate,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +--------------------------APPOS--------------------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (bezafibrate,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | | +----------------------------------APPOS----------------------------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (administration,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | | +----------------------------------APPOS----------------------------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (administration,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | +----------------------------------APPOS----------------------------------+ | | +-MOD_ATT:N-N+ +---COMP:N-N(of)---+ | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (administration,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +--------------------------APPOS--------------------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (bezafibrate,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +----------------------------------APPOS----------------------------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (administration,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | | | +--------------------------APPOS--------------------------+ | | +MOD_ATT:N-AD+ | | +-------APPOS------+ | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (bezafibrate,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | +----------------------------------APPOS----------------------------------+ | | +MOD_ATT:N-AD+ +----------------OBJ:V-N---------------+ | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ | +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) OBJ:V-N (with,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (administration,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | | +----------------------------------APPOS----------------------------------+ | | +-MOD_ATT:N-N+ | +-------APPOS------+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (administration,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | | +--------------------------APPOS--------------------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +-------APPOS------+ | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (bezafibrate,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | | +----------------------------------APPOS----------------------------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (administration,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ | +------------------COMP:N-N(with)-----------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | | | +----------------------------------APPOS----------------------------------+ | | +-MOD_ATT:N-N+ | | +-------APPOS------+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (administration,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +--------------------------APPOS--------------------------+ | | +MOD_ATT:N-AD+ +----------------OBJ:V-N---------------+ | | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ | +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) OBJ:V-N (with,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (bezafibrate,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +----------------------------------APPOS----------------------------------+ | | +MOD_ATT:N-AD+ +----------------OBJ:V-N---------------+ | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ | +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) OBJ:V-N (with,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (administration,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +-----COMP:N-N(from)----+ +-------------------------------------------SUBJ:V-N------------------------------------------+ | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+------------COMP:N-N(of)------------+ | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+------------COMP:N-N(of)------------+ | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ | | +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+------------COMP:N-N(of)------------+ | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+ | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +MOD_ATT:N-AD+ | | | +-COMP:N-N(of)-+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +MOD_ATT:N-AD+ | | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ +-----COMP:N-N(from)----+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +-MOD_ATT:N-N+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ +---COMP:N-N(of)---+ | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ | | | +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ | | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ | +------------------COMP:N-N(with)-----------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +MOD_ATT:N-AD+ | | | +-COMP:N-N(of)-+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ +---COMP:N-N(of)---+ | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +------------COMP:N-N(of)------------+ | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +-------------------COMP:N-N(of)------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ | | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ | | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ +----------------OBJ:V-N---------------+ | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ | +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) OBJ:V-N (with,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ | | | +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+ | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+ | +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +-COMP:N-N(of)-+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+ | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ +----------------OBJ:V-N---------------+ | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ | +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) OBJ:V-N (with,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+------------COMP:N-N(of)------------+ | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+ | | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ +-----COMP:N-N(from)----+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +-MOD_ATT:N-N+ +---COMP:N-N(of)---+ | +-COMP:N-N(of)-+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +-------------------COMP:N-N(of)------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | +------------COMP:N-N(of)------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ +-----COMP:N-N(from)----+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +MOD_ATT:N-AD+ | | +-COMP:N-N(of)-+ | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | +-------APPOS------+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+------------COMP:N-N(of)------------+ | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ +-------APPOS------+ +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +-----COMP:N-N(from)----+------------COMP:N-N(of)------------+ +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+ | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | +------------COMP:N-N(of)------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ +----------------OBJ:V-N---------------+ | +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ | +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) OBJ:V-N (with,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+ | +-------APPOS------+ +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ +-----COMP:N-N(from)----+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +MOD_ATT:N-AD+ +----------------OBJ:V-N---------------+ | +-COMP:N-N(of)-+ +-----COMP:V-N(to)----+ | | +MOD_AT+ | +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) OBJ:V-N (with,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ +-------APPOS------+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------------COMP:N-N(of)------------------+ | | | | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ +----------------OBJ:V-N---------------+ | +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ | +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) OBJ:V-N (with,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+ | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +----------------------------COMP:N-N(of)----------------------------+ | +------------------COMP:N-N(with)-----------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) COMP:N-N(of) (liver,__NODE__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +-MOD_ATT:N-N+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ +-----COMP:N-N(from)----+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | +MOD_ATT:N-AD+ | | +-------APPOS------+ +-COMP:N-N(of)-+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------------COMP:N-N(of)------------------+ | | | | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ +-------APPOS------+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+ | +-------APPOS------+ +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +----------------------------COMP:N-N(of)----------------------------+ | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(of) (liver,__NODE__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ | +------------------COMP:N-N(with)-----------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | | +-------APPOS------+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +----------------------------COMP:N-N(of)----------------------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+ | | | +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) COMP:N-N(of) (liver,__NODE__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ +---COMP:N-N(of)---+ | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ | | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | +-------APPOS------+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ +-------APPOS------+ +-COMP:N-N(of)-+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +----------------------------COMP:N-N(of)----------------------------+ | +------------------COMP:N-N(with)-----------------+ | | +-----COMP:N-N(from)----+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +-MOD_ATT:N-N+ | | | +-COMP:N-N(of)-+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) COMP:N-N(of) (liver,__NODE__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +-------------------COMP:N-N(of)------------------+ | | +----------------COMP:N-N(of)----------------+ | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | | +-------------------COMP:N-N(of)------------------+ | | | | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ | | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | | +-------------------COMP:N-N(of)------------------+ | | | | | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ | | | +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+ | | +-------APPOS------+ +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | +------------COMP:N-N(of)------------+ +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------------COMP:N-N(of)------------------+ | | +------------COMP:N-N(of)------------+ | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +MOD_ATT:N-AD+ | | +-COMP:N-N(of)-+ | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | | +-------------------COMP:N-N(of)------------------+ | | | | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+ | +-------APPOS------+ +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+------------COMP:N-N(of)------------+ | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ | +------------------COMP:N-N(with)-----------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ | +------------------COMP:N-N(with)-----------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+ | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ +-------APPOS------+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+ | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ +---COMP:N-N(of)---+ | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ +---COMP:N-N(of)---+ | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +------------COMP:N-N(of)------------+ | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | +-------APPOS------+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | +-------APPOS------+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ +---COMP:N-N(of)---+ | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | +------------COMP:N-N(of)------------+ | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | +------------COMP:N-N(of)------------+ | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +----------------COMP:N-N(of)----------------+ | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | +-------APPOS------+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+------------COMP:N-N(of)------------+ +----------------------------------APPOS----------------------------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (administration,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | +----------------------------------APPOS----------------------------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (administration,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | +----------------------------------APPOS----------------------------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (administration,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | +----------------------------------APPOS----------------------------------+ | | +MOD_ATT:N-AD+ | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (administration,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | +--------------------------APPOS--------------------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+ | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (bezafibrate,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ | +------------------COMP:N-N(with)-----------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +--------------------------APPOS--------------------------+ | | +-MOD_ATT:N-N+ | | +---MOD_ATT:N-ADJ--+ | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (bezafibrate,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +--------------------------APPOS--------------------------+ | | +MOD_ATT:N-AD+ | | +---MOD_ATT:N-ADJ--+ | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (bezafibrate,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ +----------------------------------APPOS----------------------------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+ | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (administration,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | +----------------------------------APPOS----------------------------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (administration,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +--------------------------APPOS--------------------------+ | | +-MOD_ATT:N-N+ +---COMP:N-N(of)---+ | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (bezafibrate,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +----------------------------------APPOS----------------------------------+ | | +MOD_ATT:N-AD+ | | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (administration,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +--------------------------APPOS--------------------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (bezafibrate,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+ +----------------------------------APPOS----------------------------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (administration,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | +----------------------------------APPOS----------------------------------+ | | +-MOD_ATT:N-N+ +---COMP:N-N(of)---+ | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (administration,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | | +--------------------------APPOS--------------------------+ | | +-MOD_ATT:N-N+ | +-------APPOS------+ | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (bezafibrate,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +--------------------------APPOS--------------------------+ | | +MOD_ATT:N-AD+ | | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (bezafibrate,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | | | +----------------------------------APPOS----------------------------------+ | | +MOD_ATT:N-AD+ | | +-------APPOS------+ +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (administration,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | | +----------------------------------APPOS----------------------------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (administration,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ | +------------------COMP:N-N(with)-----------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | | | +--------------------------APPOS--------------------------+ | | +-MOD_ATT:N-N+ | | +-------APPOS------+ | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (bezafibrate,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+------------COMP:N-N(of)------------+ | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +-----COMP:N-N(from)----+ +-------------------------------------------SUBJ:V-N------------------------------------------+ | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+------------COMP:N-N(of)------------+ | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ +-----COMP:N-N(from)----+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ | | +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+------------COMP:N-N(of)------------+ | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ | | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ | +------------------COMP:N-N(with)-----------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ | +------------------COMP:N-N(with)-----------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ +-----COMP:N-N(from)----+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +-MOD_ATT:N-N+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ | | | +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ +-------APPOS------+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ | +------------------COMP:N-N(with)-----------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +MOD_ATT:N-AD+ | | | +-COMP:N-N(of)-+ | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +------------COMP:N-N(of)------------+ | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +------------COMP:N-N(of)------------+ | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+ | +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +-------------------COMP:N-N(of)------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ | | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+ | | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +MOD_ATT:N-AD+ | | | +-COMP:N-N(of)-+ | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ | | | +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+------------COMP:N-N(of)------------+ | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | +-------APPOS------+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ +-----COMP:N-N(from)----+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+ | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +-------------------COMP:N-N(of)------------------+ | | +------------COMP:N-N(of)------------+ | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------------COMP:N-N(of)------------------+ | | | | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +-------------------COMP:N-N(of)------------------+ | | +------------COMP:N-N(of)------------+ | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | +-------APPOS------+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ +----------------OBJ:V-N---------------+ | +-COMP:N-N(of)-+ | | | | | +MOD_AT+ | +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) OBJ:V-N (with,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+ +---COMP:N-N(of)---+ | +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | +------------COMP:N-N(of)------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ +-----COMP:N-N(from)----+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | +-MOD_ATT:N-N+ | +-------APPOS------+ +-COMP:N-N(of)-+ | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ +-----COMP:N-N(from)----+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | +MOD_ATT:N-AD+ | | +-------APPOS------+ +-COMP:N-N(of)-+ | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+ | | +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ +-------APPOS------+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ +----------------OBJ:V-N---------------+ | +-COMP:N-N(of)-+ | | | | | +MOD_AT+ | +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) OBJ:V-N (with,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ +-----COMP:N-N(from)----+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +-MOD_ATT:N-N+ | | +-COMP:N-N(of)-+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +----------------------------COMP:N-N(of)----------------------------+ | +------------------COMP:N-N(with)-----------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) COMP:N-N(of) (liver,__NODE__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ | | +-------APPOS------+ +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+ | +-------APPOS------+ +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+ | +-------APPOS------+ +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +----------------------------COMP:N-N(of)----------------------------+ | +-----COMP:N-N(from)----+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(of) (liver,__NODE__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ +-------APPOS------+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+ | +-------APPOS------+ +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ +---COMP:N-N(of)---+ | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +----------------------------COMP:N-N(of)----------------------------+ | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(of) (liver,__NODE__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ +-------APPOS------+ +-COMP:N-N(of)-+ | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ | | +-------APPOS------+ +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | +------------COMP:N-N(of)------------+ | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------------COMP:N-N(of)------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ +-------APPOS------+ +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+ | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +-------------------COMP:N-N(of)------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+ | +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | +-------APPOS------+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | +----------------COMP:N-N(of)----------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | | +-------------------COMP:N-N(of)------------------+ | | | | | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ | | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | +------------COMP:N-N(of)------------+ | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ | | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | | +-------------------COMP:N-N(of)------------------+ | | | | | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ | | | +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+ | | +-------APPOS------+ +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | | +-------------------COMP:N-N(of)------------------+ | | | | | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ | | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ | | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | | +-------------------COMP:N-N(of)------------------+ | | | | | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ | | | +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +-------------------COMP:N-N(of)------------------+ | | +----------------COMP:N-N(of)----------------+ | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | +------------COMP:N-N(of)------------+ +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+ | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------------COMP:N-N(of)------------------+ | | | | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+ | | +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------------COMP:N-N(of)------------------+ | | | | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+ | | +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | | | +-------------------COMP:N-N(of)------------------+ | | | | | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ | | +-------APPOS------+ +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ +---COMP:N-N(of)---+ | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ +-------APPOS------+ +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ | +------------------COMP:N-N(with)-----------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ | +------------------COMP:N-N(with)-----------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ +---COMP:N-N(of)---+ | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ +-------APPOS------+ +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +------------COMP:N-N(of)------------+ | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+----------------COMP:N-N(of)----------------+ | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | +-------APPOS------+ +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +------------COMP:N-N(of)------------+ | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | +-------APPOS------+ +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ +----------------OBJ:V-N---------------+ | +-COMP:N-N(of)-+ | | | | +MOD_AT+ | +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) OBJ:V-N (with,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ +----------------OBJ:V-N---------------+ | +-COMP:N-N(of)-+ | | | | +MOD_AT+ | +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) OBJ:V-N (with,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | +-------APPOS------+ +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+---COMP:N-N(of)---+ | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__NODE__) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ +-------APPOS------+ +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ | | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ | +------------------COMP:N-N(with)-----------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | | +-------APPOS------+ +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ | | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | +------------COMP:N-N(of)------------+ | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | +-------APPOS------+ +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ +----------------OBJ:V-N---------------+ | +-COMP:N-N(of)-+ | | | | +MOD_AT+ | +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) OBJ:V-N (with,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +--------------------------APPOS--------------------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (bezafibrate,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | +----------------------------------APPOS----------------------------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (administration,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +----------------------------------APPOS----------------------------------+ | | +-MOD_ATT:N-N+ | | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (administration,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +----------------------------------APPOS----------------------------------+ | | +-MOD_ATT:N-N+ | | | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (administration,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +--------------------------APPOS--------------------------+ | | +MOD_ATT:N-AD+ | | | | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (bezafibrate,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ | +------------------COMP:N-N(with)-----------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +--------------------------APPOS--------------------------+ | | +-MOD_ATT:N-N+ | | | | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (bezafibrate,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | +----------------------------------APPOS----------------------------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (administration,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +--------------------------APPOS--------------------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (bezafibrate,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +------------COMP:N-N(of)------------+ | +--------------------------APPOS--------------------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (bezafibrate,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | +----------------------------------APPOS----------------------------------+ | | +-MOD_ATT:N-N+ | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (administration,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | +----------------------------------APPOS----------------------------------+ | | +-MOD_ATT:N-N+ +----------------OBJ:V-N---------------+ | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ | +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) OBJ:V-N (with,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (administration,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | | +--------------------------APPOS--------------------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +-------APPOS------+ | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (bezafibrate,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | | +--------------------------APPOS--------------------------+ | | +MOD_ATT:N-AD+ | | | | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (bezafibrate,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +----------------------------------APPOS----------------------------------+ | | +-MOD_ATT:N-N+ | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (administration,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +----------------------------------APPOS----------------------------------+ | | +-MOD_ATT:N-N+ +----------------OBJ:V-N---------------+ | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ | +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) OBJ:V-N (with,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (administration,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +-----COMP:N-N(from)----+ +-------------------------------------------SUBJ:V-N------------------------------------------+ | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +-COMP:N-N(of)-+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +-----COMP:N-N(from)----+ +-------------------------------------------SUBJ:V-N------------------------------------------+ | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +-COMP:N-N(of)-+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +-----COMP:N-N(from)----+------------COMP:N-N(of)------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +-----COMP:N-N(from)----+------------COMP:N-N(of)------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ | | | +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +-MOD_ATT:N-N+ | | | +-COMP:N-N(of)-+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+ | | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +-COMP:N-N(of)-+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+ | | | +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+ | | | +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +MOD_ATT:N-AD+ | | | +-COMP:N-N(of)-+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +------------COMP:N-N(of)------------+ | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+ | | | +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+ | | | +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ +-----COMP:N-N(from)----+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | | +-------APPOS------+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ +----------------OBJ:V-N---------------+ | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ | +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) OBJ:V-N (with,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+ +----------------OBJ:V-N---------------+ | +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ | +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) OBJ:V-N (with,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+ | | +-------APPOS------+ +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+ | | +-------APPOS------+ +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+ | | +-------APPOS------+ +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ | | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +MOD_ATT:N-AD+ | | | +-COMP:N-N(of)-+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | | +-------------------COMP:N-N(of)------------------+ | | | | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ +----------------OBJ:V-N---------------+ | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ | +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) OBJ:V-N (with,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ | | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | | +-------------------COMP:N-N(of)------------------+ | | | | | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+ | | | +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | | +-------------------COMP:N-N(of)------------------+ | | | | | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+ | | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ | | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +-MOD_ATT:N-N+ | | | +-COMP:N-N(of)-+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | +-MOD_ATT:N-N+ | | +-------APPOS------+ +-COMP:N-N(of)-+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------------COMP:N-N(of)------------------+ | | | | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+ +----------------OBJ:V-N---------------+ | +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ | +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) OBJ:V-N (with,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | | | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +------------COMP:N-N(of)------------+ | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ +----------------OBJ:V-N---------------+ | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ | +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) OBJ:V-N (with,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | | +-------APPOS------+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | | +-------APPOS------+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | | +-------APPOS------+ +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +--------------------------APPOS--------------------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (bezafibrate,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +--------------------------APPOS--------------------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (bezafibrate,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | +----------------------------------APPOS----------------------------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (administration,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +--------------------------APPOS--------------------------+ | | +-MOD_ATT:N-N+ | | | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (bezafibrate,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | +----------------------------------APPOS----------------------------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (administration,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +--------------------------APPOS--------------------------+ | | +MOD_ATT:N-AD+ | | | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (bezafibrate,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | | +----------------------------------APPOS----------------------------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (administration,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +------------COMP:N-N(of)------------+ +----------------------------------APPOS----------------------------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (administration,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +----------------------------------APPOS----------------------------------+ | | +-MOD_ATT:N-N+ | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (administration,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | | +--------------------------APPOS--------------------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +-------APPOS------+ | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (bezafibrate,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | | +----------------------------------APPOS----------------------------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (administration,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | | | +--------------------------APPOS--------------------------+ | | +-MOD_ATT:N-N+ | | +-------APPOS------+ | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (bezafibrate,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ +-----COMP:N-N(from)----+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+ | | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ | +-----COMP:N-N(from)----+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ | | | +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+ | | | +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ | +------------------COMP:N-N(with)-----------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ | | | +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +-MOD_ATT:N-N+ | | | +-COMP:N-N(of)-+ | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+ | | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +-------------------COMP:N-N(of)------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ | | | +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +-MOD_ATT:N-N+ | | | +-COMP:N-N(of)-+ | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ +----------------OBJ:V-N---------------+ | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ | +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) OBJ:V-N (with,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+ | | | +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +------------COMP:N-N(of)------------+ | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+ | | | +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | | +-------APPOS------+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------------COMP:N-N(of)------------------+ | | | | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------------COMP:N-N(of)------------------+ | | | | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------------COMP:N-N(of)------------------+ | | | | | +-------------COMP:N-N(of)-------------+ | | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------------COMP:N-N(of)------------------+ | | | | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ +-----COMP:N-N(from)----+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | +-MOD_ATT:N-N+ | | +-------APPOS------+ +-COMP:N-N(of)-+ | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +-------------------COMP:N-N(of)------------------+ | | +------------COMP:N-N(of)------------+ | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ +-----COMP:N-N(from)----+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +-MOD_ATT:N-N+ +----------------OBJ:V-N---------------+ | +-COMP:N-N(of)-+ | | | +MOD_AT+ | +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) OBJ:V-N (with,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+ | | +-------APPOS------+ +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+ | | +-------APPOS------+ +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+ +----------------OBJ:V-N---------------+ | +-COMP:N-N(of)-+ | | | | | +MOD_AT+ | +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) OBJ:V-N (with,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------------COMP:N-N(of)------------------+ | | | | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+ | | +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ | | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+ | | +-------APPOS------+ +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------------COMP:N-N(of)------------------+ | | | | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+ | | +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ | | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | | +-------APPOS------+ +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+ | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ +----------------OBJ:V-N---------------+ | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ | +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) OBJ:V-N (with,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ | | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | | +-------------------COMP:N-N(of)------------------+ | | | | | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+ | | | +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +-MOD_ATT:N-N+ +----------------OBJ:V-N---------------+ | +-COMP:N-N(of)-+ | | | +MOD_AT+ | +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) OBJ:V-N (with,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | | | +-------------------COMP:N-N(of)------------------+ | | | | | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+ | | +-------APPOS------+ +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | | | +-------------------COMP:N-N(of)------------------+ | | | | | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+ | | +-------APPOS------+ +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +---MOD_ATT:N-ADJ--+ +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,__NODE__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+COMP:N-N(o+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+------------COMP:N-N(of)------------+ | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) COMP:N-N(of) (__SP__,__SP__) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +MOD_ATT:N-AD+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-ADJ (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ +------------------------COMP:N-N(of)------------------------+ | +------------------COMP:N-N(with)-----------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) COMP:N-N(of) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | +-------APPOS------+ +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +--------------------------------------------------COMP:V-N(of)--------------------------------------------------+ | | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ +MOD_ATT+ +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (__NODE__,__SP__) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__NODE__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | | +----------------------------------------------------SUBJ:V-N----------------------------------------------------+ | | | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | | +-------APPOS------+ +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) APPOS (__NODE__,administration) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,__NODE__) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ +----------------OBJ:V-N---------------+ | +-COMP:N-N(of)-+ | | | | +MOD_AT+ | +MOD_ATT:N+COMP:N-N(o+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) OBJ:V-N (with,__NODE__) MOD_ATT:N-ADJ (knockout,homozygous) COMP:N-N(of) (knockout,__SP__) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +--------------------------APPOS--------------------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (bezafibrate,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | +----------------------------------APPOS----------------------------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (administration,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +----------------------------------APPOS----------------------------------+ | | +-MOD_ATT:N-N+ | | | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (administration,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+ | | | +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+ | | | +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+ | | | +-COMP:N-N(of)-+ | | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | | | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | | | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | | | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | +-----COMP:V-N(to)----+ | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+ | | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:V-N(to) (increase,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +--------------------------APPOS--------------------------+ | | +-MOD_ATT:N-N+ | | | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (bezafibrate,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +--------------------------APPOS--------------------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (bezafibrate,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +--------------------------APPOS--------------------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (bezafibrate,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | | +--------------------------APPOS--------------------------+ | | +-MOD_ATT:N-N+ | | | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) APPOS (bezafibrate,period) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | | | +-COMP:N-N(of)-+-----------COMP:N-N(of)-----------+ | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) COMP:N-N(of) (percent,year) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +------------------COMP:N-N(with)-----------------+ | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+ | | | +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) COMP:N-N(with) (liver,knockout) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ +-----COMP:N-N(from)----+ | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +-MOD_ATT:N-N+ | | | +-COMP:N-N(of)-+ | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------------COMP:N-N(of)------------------+ | +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+ | | | +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------------COMP:N-N(of)------------------+ | | | | | +-------------COMP:N-N(of)-------------+ | | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+ | +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) COMP:N-N(of) (dosage,year) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | +-MOD_ATT:N-N+ | | | +-COMP:N-N(of)-+ | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ +-----COMP:N-N(from)----+ | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . COMP:N-N(from) (liver,__SP__) MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-N (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+------COMP:N-N(with)-----+ | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) COMP:N-N(with) (__SP__,knockout) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
+-------------------------------------------------------------------------------------COMP:V-N(In)------------------------------------------------------------------------------------+ | +------------------------------------------------------------------------COMP:V-N(from)-----------------------------------------------------------------------+ | | +-----------------------------------------------------------COMP:V-N(with)----------------------------------------------------------+ | | | +------------------------------------------------------COMP:V-N(of)------------------------------------------------------+ | | | | +-------------------------------------------SUBJ:V-N------------------------------------------+ | | | | | +-------------COMP:N-N(of)-------------+ | | +-MOD_ATT:N-N+ | | | +-COMP:N-N(of)-+ | | | | +MOD_AT+ +MOD_ATT:N+ | +MOD_ATT:N+--COMP:N-N(of)-+ | +MOD_A+ +MOD_ATT:+COMP:N-N(o+ +-OBJ:V-N-+COMP:N-N(to+ | | | | | | | | | | | | | | | | | | | In liver from male mutant __SP__ with a homozygous knockout of __SP__ __NODE__ , oral administration of bezafibrate ( with a dosage of 00.5 percent and a treatment period of 1 year ) increases formation to adenoma . MOD_ATT:N-N (__SP__,male) MOD_ATT:N-ADJ (__SP__,mutant) MOD_ATT:N-ADJ (knockout,homozygous) MOD_ATT:N-ADJ (administration,oral) COMP:N-N(of) (administration,bezafibrate) COMP:N-N(of) (dosage,percent) COMP:N-N(of) (dosage,period) MOD_ATT:N-ADJ (percent,@card@) MOD_ATT:N-N (period,treatment) COMP:N-N(of) (period,year) COMP:V-N(In) (increase,liver) COMP:V-N(from) (increase,__SP__) COMP:V-N(with) (increase,knockout) COMP:V-N(of) (increase,__SP__) SUBJ:V-N (increase,administration) OBJ:V-N (increase,formation) COMP:N-N(to) (formation,adenoma)
